Replies to post #8740 on SEASONALITY STOCK REPORTS

[flota]

42B2

PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED NOVEMBER 5, 2003

12,000,000 SHARES OF COMMON STOCK

[PEREGRINE LOGO]

Unless the context otherwise requires, all references to "we," "us," or
"our" in this prospectus supplement refer to Peregrine Pharmaceuticals, Inc., a
Delaware corporation.

This Prospectus Supplement and the attached Prospectus relate to the
offering and sale of 551,029 shares of our common stock, par value $0.001 per
share, to Affitech AS in payment of (i) an initial technology access fee due
under an Antibody Development Collaboration dated November 4, 2004 pertaining to
the production of fully human monoclonal antibodies against up to six antibody
targets and (ii) certain amounts due under a separate Antibody Research
Collaboration dated September 23, 2004 for development services pertaining to
the generation of a fully human antibody under our Anti-Phospholipid Therapy
technology platform.

[kgoodrich]

I saw that Friday been there.
Someone must have inherited some shares and has the option to sell by a certain date. I don't think they'll sell with news on the way. They haven't sold yet. I did notice the competition section of the form where PPHM has their drugs in phases's I and II, while others have theirs in III. But, they don't have the drug that PPHM has. I am confident there will be something good to come out of this.